Cited by 1,730Renal cell carcinoma treatmentEar and Head TumorsCancer, Hypoxia, and Metabolism

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Mutations of the VHL tumour suppressor gene in renal carcinoma

Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D.R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N.H., Grossman, H.B., Brauch, H., Pomer, S., Brooks, J.D., Isaacs, W.B., Lerman, M.I., Zbar, B., Linehan, W.M.·1994·Nature Genetics

DOI 10.1038/ng0594-85

Open this paper in CoChat — free account

Abstract

Multiple, bilateral renal carcinomas are a frequent occurrence in von Hippel-Lindau (VHL) disease. To elucidate the aetiological role of the VHL gene in human kidney tumorigenesis, localized and advanced tumours from 110 patients with sporadic renal carcinoma were analysed for VHL mutations and loss of heterozygosity (LOH). VHL mutations were identified in 57% of clear cell renal carcinomas analysed and LOH was observed in 98% of those samples. Moreover, VHL was mutated and lost in a renal tumour from a patient with familial renal carcinoma carrying the constitutional translocation, t(3;8)(p14;q24). The identification of VHL mutations in a majority of localized and advanced sporadic renal carcinomas and in a second form of hereditary renal carcinoma indicates that the VHL gene plays a critical part in the origin of this malignancy.

Integrity signals

Registry

Crossref · 10.1038/ng0594-85

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J. R., Yao, M., Duh, F.-M. C., Orcutt, M. L., Stackhouse, T. M., Kuzmin, I., Modi, W. S., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,971
Self-citation
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (1969) · The Journal of Urology · doi:10.1016/s0022-5347(17)62331-0 · Cited by 1,303
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P. J., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,298
Hereditary cancer, oncogenes, and antioncogenes.
Knudson, A. G. (1985) · PubMed · Cited by 1,218
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.10.095 · Cited by 1,160
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Höppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,143
Diseases of the kidney
Strauss, M. B., & Welt, L. G. (1963) · Little, Brown eBooks · Cited by 823
Mutations of the RET proto-oncogene in Hirschsprung's disease
Edery, P., Lyonnet, S., Mulligan, L. M., Pelet, A., Dow, E., Abel, L., Holder, S., Nihoul‐Feketé, C., Ponder, B. A. J., & Münnich, A. (1994) · Nature · doi:10.1038/367378a0 · Cited by 746
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease
Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kääriäinen, H., et al. (1994) · Nature · doi:10.1038/367377a0 · Cited by 698
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D. G., Kwok, J. B., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-70 · Cited by 643

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 1

Glenn, G.M., Choyke, P.L., Zbar, B. & Linehan, W.M. von Hippel-Lindau disease: clinical review and molecular genetics. Problems Urol. 4, 312–330 (1990).

Sorted by citations

Items 801–900 of 1,002

Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone)
Skálová, A., Šíma, R., Bohus, P., Curik, R., Lukáš, J., & Michal, M. (2008) · Pathology - Research and Practice · doi:10.1016/j.prp.2008.01.016 · Cited by 28
MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway
Bouillez, A., Gnemmi, V., Gaudelot, K., Hémon, B., Ringot-Destrez, B., Pottier, N., Glowacki, F., Butruille, C., Cauffiez, C., Hamdane, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1768 · Cited by 28
Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein
Minervini, G., Mazzotta, G. M., Masiero, A., Sartori, E., Corrà, S., Potenza, E., Costa, R., & Tosatto, S. C. E. (2015) · Scientific Reports · doi:10.1038/srep12605 · Cited by 28
Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets
Testa, U., Pelosi, E., & Castelli, G. (2020) · Medicines · doi:10.3390/medicines7080044 · Cited by 30
Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element
Kageyama, Y., Sugiyama, H., Ayame, H., Iwai, A., Fujii, Y., Huang, E. L., Kizaka‐Kondoh, S., Hiraoka, M., & Kihara, K. (2006) · Acta Oncologica · doi:10.1080/02841860500486648 · Cited by 30
Molecular Genetic Alterations in Adrenal and Extra-Adrenal Pheochromocytomas and Paragangliomas
Dannenberg, H., Komminoth, P., Dinjens, W. N. M., Speel, E. M., & de Krijger, R. R. (2003) · Endocrine Pathology · doi:10.1385/ep:14:4:329 · Cited by 28
Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factors
Hemminki, K. (2002) · Carcinogenesis · doi:10.1093/carcin/23.5.809 · Cited by 28
Two distinct phenotypes caused by two different missense mutations in the same codon of the VHL gene
Bradley, J. F., Collins, D. L., Schimke, R. N., Parrott, H. N., & Rothberg, P. G. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19991119)87:2 · Cited by 28
A group of notI jumping and linking clones cover 2.5 Mb in the 3p21–p22 region suspected to contain a tumor suppressor gene
Kashuba, V. I., Szeles, A., Allikmets, R. L., Nilsson, A.-S., Bergerheim, U. S. R., Modi, W. S., Graphodatsky, A. S., Dean, M. C., Stanbridge, E. J., Winberg, G., et al. (1995) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(94)00215-w · Cited by 28
VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma
Lessi, F., Mazzanti, C. M., Tomei, S., Cristofano, C. D., Minervini, A., Menicagli, M., Apollo, A., Masieri, L., Collecchi, P., Minervini, R., et al. (2014) · Medical Oncology · doi:10.1007/s12032-014-0840-8 · Cited by 27
Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma
Wang, Z., Wei, J., Zhou, J.-C., Haddad, A., Zhao, L.-Y., Kapur, P., Wu, K.-J., Wang, B., Yu, Y., Liao, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8971 · Cited by 27
Mitochondrial disorders in renal tumors
Hervouet, É., & Godinot, C. (2006) · Mitochondrion · doi:10.1016/j.mito.2006.03.003 · Cited by 27
Identification of Ror2 as a Hypoxia-inducible Factor Target in von Hippel-Lindau-associated Renal Cell Carcinoma
Wright, T. M., & Rathmell, W. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073924 · Cited by 27
Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation
Greene, C., Sharma, N. J., Fiorica, P. N., Forrester, E. J., Smith, G. J., Gross, K. W., & KAUFFMAN, E. C. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.12.013 · Cited by 28
Targeting VEGF in Cancer Therapy
Donovan, E. A., & Kummar, S. (2006) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2005.11.001 · Cited by 27
Solitary retinal capillary hemangioma: Lack of genetic evidence for von Hippel-Lindau disease
Singh, A. D., Ahmad, N. R. B. B. N., Shields, C. L., & Shields, J. A. (2002) · Ophthalmic Genetics · doi:10.1076/opge.23.1.21.2201 · Cited by 27
DNA Methylation
Singal, R., & Ginder, G. D. (1999) · Blood · doi:10.1182/blood.v93.12.4059.412k40_4059_4070 · Cited by 27
The place of VEGF inhibition in the current management of renal cell carcinoma
for the London Biological and Targeted Therapy Group, Nathan, P., Chao, D., Brock, C., Savage, P. M., Harries, M., Gore, M. E., & Eisen, T. G. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603025 · Cited by 27
High cell density induces vascular endothelial growth factor expression via protein tyrosine phosphorylation.
Mukhopadhyay, D., Tsiokas, L., & Sukhatme, V. P. (1998) · Europe PMC (PubMed Central) · Cited by 27
Von Hippel-Lindau Disease: Genetic and Clinical Observations
Iliopoulos, O. (2001) · KARGER eBooks · doi:10.1159/000061052 · Cited by 27
The von Hippel-Lindau Tumor Suppressor Gene Product Promotes, but Is Not Essential for, NEDD8 Conjugation to Cullin-2
Wada, H., Yeh, E. T. H., & Kamitani, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.36025 · Cited by 27
Single‐cell analysis reveals metastatic cell heterogeneity in clear cell renal cell carcinoma
Liu, K., Gao, R., Wu, H., Wang, Z., & Han, G. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16479 · Cited by 26
Ginsenoside Rh2 sensitizes the anti-cancer effects of sunitinib by inducing cell cycle arrest in renal cell carcinoma
Hwang, H. J., Hong, S. H., Moon, H. S., Yoon, Y. E., & Park, S. Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-20075-0 · Cited by 26
When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Wu, Z., & Shi, Y. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180010 · Cited by 26
Circulating Biomarkers in Advanced Renal Cell Carcinoma: Clinical Applications
Hernandez-Yanez, M., Heymach, J. V., & Zurita, A. J. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0231-2 · Cited by 26
TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe
Szymańska, K., Moore, L. E., Rothman, N., Chow, W., Waldman, F. M., Jaeger, E., Waterboer, T., Foretová, L., Navrátilová, M., Janout, V., et al. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.11.024 · Cited by 26
The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
Azijli, K., Gotink, K. J., & Verheul, H. M. W. (2016) · Journal of Kidney Cancer and VHL · doi:10.15586/jkcvhl.2015.44 · Cited by 26
Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma
Hou, W., & Ji, Z. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0059-4 · Cited by 28
Cloning a calcium channel α2δ-3 subunit gene from a putative tumor suppressor gene region at chromosome 3p21.1 in conventional renal cell carcinoma
Hanke, S., Bugert, P., Chudek, J. T., & Kovacs, G. (2001) · Gene · doi:10.1016/s0378-1119(00)00600-4 · Cited by 26
Losses at 3p common deletion sites in subtypes of kidney tumours: histopathological correlations
Hadaczek, P., Podolski, J., Toloczko, A. D., Kurzawski, G., Lubiński, J., Sikorski, A., Rabbitts, P. H., & Huebner, K. (1996) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00196818 · Cited by 26
Characterization of the Gene (VBP1) and Transcript for the von Hippel–Lindau Binding Protein and Isolation of the Highly Conserved Murine Homologue
Brinke, A., Green, P. M., & Giannelli, F. (1997) · Genomics · doi:10.1006/geno.1997.4902 · Cited by 26
Somatic von Hippel–Lindau disease gene mutation in clear‐cell renal carcinomas associated with end‐stage renal disease/acquired cystic disease of the kidney
Yoshida, M., Yao, M., Ishikawa, I., Kishida, T., Nagashima, Y., Kondo, K., Nakaigawa, N., & Hosaka, M. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10123 · Cited by 26
Von Hippel–Lindau disease germline mutations in Mexican patients with cerebellar hemangioblastoma
Rasmussen, A., Nava-Salazar, S., Yescas, P., Alonso, E., Revuelta, R., Ortiz, I. P., Canizales‐Quinteros, S., Tusié-Luna, M. T., & López, M. (2006) · Journal of neurosurgery · doi:10.3171/jns.2006.104.3.389 · Cited by 26
Sunitinib
Heng, D. Y. C., & Kollmannsberger, C. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-01222-8_6 · Cited by 27
Development of High‐grade Renal Cell Carcinomas in Rats Independently of Somatic Mutations in the Tsc2 and VHL Tumor Suppressor Genes
Toyokuni, S., Okada, K., Kondo, S., Nishioka, H., Tanaka, T., Nishiyama, Y., Hino, O., & Hiai, H. (1998) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1998.tb00633.x · Cited by 26
Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
Isaacs, J. S. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.569 · Cited by 26
Functioning Thoracic Paraganglioma: Association with Von Hippel-Lindau Syndrome
Bender, B., Altehöfer, C., Januszewicz, A., Gärtner, R., Schmidt, H., Hoffmann, M. M., Heidemann, P. H., & Neumann, H. P. H. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.10.3356 · Cited by 26
Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer Systematic Review
Zgura, A. F., Chipuc, S., Bacalbaşa, N., Hăineală, B., Maricela, A. R., & Vâlcea, S. (2025) · Cancers · doi:10.3390/cancers17030480 · Cited by 25
Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC)
Singh, R. B., & Kadam, P. S. A. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.08.012 · Cited by 25
Genome‐wide analysis of DNA methylation identifies the apoptosis‐related gene UQCRH as a tumor suppressor in renal cancer
Miyakuni, K., Nishida, J., Koinuma, D., Nagae, G., Aburatani, H., Miyazono, K., & Ehata, S. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13040 · Cited by 25
Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma
Sonpavde, G., Willey, C. D., & Sudarshan, S. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.871259 · Cited by 25
Inhibition of mTORC2 but not mTORC1 Up-Regulates E-Cadherin Expression and Inhibits Cell Motility by Blocking HIF-2α Expression in Human Renal Cell Carcinoma
Maru, S., Ishigaki, Y., Shinohara, N., Takata, T., Tomosugi, N., & Nonomura, K. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.11.010 · Cited by 25
Targeting ion transport in cancer
Oosterwijk, E., & Gillies, R. J. (2014) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0107 · Cited by 25
Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma
Bielecka, Z. F., Czarnecka, A. M., & Szczylik, C. A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00194 · Cited by 25
PGC1α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression
Nam, H., Kundu, A., Brinkley, G. J., Chandrashekar, D. S., Kirkman, R. L., Chakravarthi, B. V. S. K., Orlandella, R. M., Norian, L. A., Sonpavde, G., Ghatalia, P., et al. (2020) · Matrix Biology · doi:10.1016/j.matbio.2020.01.001 · Cited by 25
The pVHL neglected functions, a tale of hypoxia-dependent and -independent regulations in cancer
Minervini, G., Pennuto, M., & Tosatto, S. C. E. (2020) · Open Biology · doi:10.1098/rsob.200109 · Cited by 25
Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype.
Gruys, M. E., Back, T. C., Subleski, J. J., Wiltrout, T. A., Lee, J. K., Schmidt, L. S., Watanabe, M., Stanyon, R., Ward, J. M., Wigginton, J. M., et al. (2001) · PubMed · Cited by 25
Self-citation
Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant
Wang, Y., Wang, X.-Y., Subjeck, J. R., & Kim, H. L. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0603 · Cited by 25
The second ETV6 allele is not necessarily deleted in acute leukemias with aETV6/ABL fusion
Hannemann, J., Healy, L. E., Ridge, S. A., & Wiedemann, L. M. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199803)21:3 · Cited by 8
Self-citation
Aberrations of the p14ARF and p16INK4a Genes in Renal Cell Carcinomas
Kawada, Y., Nakamura, M., Ishida, E., Shimada, K., Oosterwijk, E., Uemura, H., Hirao, Y., Chul, K. S., & Konishi, N. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb02152.x · Cited by 25
Use of the Spontaneous Tsc2 Knockout (Eker) Rat Model of Hereditary Renal Cell Carcinoma for the Study of Renal Carcinogens
McDorman, K. S., & Wolf, D. C. (2002) · Toxicologic Pathology · doi:10.1080/01926230290168542 · Cited by 25
Visual inspection with acetic acid in the early detection of cervical cancer and precursors
Sankaranarayanan, R., Shyamalakumary, B., Wesley, R., Amma, N. S., Parkin, D. M., & Nair, M. K. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990105)80:1 · Cited by 114
Combined classical cytogenetics and microarray‐based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma
Pei, J., Feder, M., Al‐Saleem, T., Liu, Z., Liu, A., Hudes, G. R., Uzzo, R. G., & Testa, J. R. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20771 · Cited by 24
An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma
Gossage, L., Pires, D. E. V., Olivera‐Nappa, Á., Asenjo, J. A., Bycroft, M., Blundell, T. L., & Eisen, T. G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu321 · Cited by 25
Oncogenic miR‑425‑5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma
Quan, J., Li, Y., Pan, X., Lai, Y., He, T., Lin, C., Zhou, L., Zhao, L., Sun, S., Ding, Y., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8948 · Cited by 24
The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma
Naik, P., Dudipala, H. R., Chen, Y., Rose, B. S., Bagrodia, A., & McKay, R. R. (2024) · Therapeutic Advances in Urology · doi:10.1177/17562872241232578 · Cited by 24
Pathological and Clinical Features and Management of Central Nervous System Hemangioblastomas in von Hippel-Lindau Disease
Kanno, H., Kobayashi, N., & Nakanowatari, S. (2014) · Journal of Kidney Cancer and VHL · doi:10.15586/jkcvhl.2014.12 · Cited by 24
SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells
Bonnet, M., Flanagan, J. U., Chan, D. A., Lai, E. W., Nguyen, P., Giaccia, A. J., & Hay, M. P. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.04.042 · Cited by 24
Mutational Analysis of the von Hippel Lindau Gene in Clear Cell Renal Carcinomas from Tuberous Sclerosis Complex Patients
Duffy, K., Al‐Saleem, T., Karbowniczek, M., Ewalt, D. H., Prowse, A. H., & Henske, E. P. (2002) · Modern Pathology · doi:10.1038/modpathol.3880517 · Cited by 24
Impact of Genetics on the Diagnosis and Treatment of Renal Cancer
Singer, E. A., Bratslavsky, G., Middelton, L. A., Srinivasan, R., & Linehan, W. M. (2010) · Current Urology Reports · doi:10.1007/s11934-010-0156-y · Cited by 24
Self-citation
Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib
Peltola, K. J., Penttilä, P., Rautiola, J., Joensuu, H., Hänninen, E., Ristimaki, A. P., & Bono, P. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.01.021 · Cited by 24
Microarrays for Personalized Genomic Medicine
Lam, C., Lau, K., & Tong, S.-F. (2010) · Advances in clinical chemistry · doi:10.1016/s0065-2423(10)52001-8 · Cited by 24
Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma
Garrigós, C., Espinosa, M., Salinas, A. M., Osman, I., López, R. A. M., Tarón, M., Molina‐Pinelo, S., & Durán, I. (2017) · Oncotarget · doi:10.18632/oncotarget.22533 · Cited by 24
von Hippel-Lindau Disease: an Update
Maher, E. R., & Sandford, R. N. (2019) · Current Genetic Medicine Reports · doi:10.1007/s40142-019-00180-9 · Cited by 25
NNT‐induced tumor cell “slimming” reverses the pro‐carcinogenesis effect of HIF2a in tumors
Xiong, Z., Xiong, W., Xiao, W., Yuan, C., Shi, J., Huang, Y., Wang, C., Meng, X., Chen, Z., Yang, H., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.264 · Cited by 24
Current management of renal cell carcinoma and targeted therapy.
Canda, A. E., & Kırkalı, Z. (2006) · Urology journal./Urology jornal. · Cited by 24
The Tumor-Suppressive Function of UNC5D and Its Repressed Expression in Renal Cell Carcinoma
Lü, D., Dong, D., Zhou, Y. J., Lu, M., Pang, X., Li, Y., Tian, X., Zhang, Y., & Zhang, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2978 · Cited by 24
Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling
Takahashi, M., Teh, B. T., & Kanayama, H. (2006) · The Journal of Medical Investigation · doi:10.2152/jmi.53.9 · Cited by 24
The allelic loss of chromosome 3p25 with c‐myc gain is related to the development of clear‐cell renal cell carcinoma
Yamaguchi, S., Yoshihiro, S., Matsuyama, H., Nagao, K., Fukunaga, K., Matsumoto, H., Matsuda, K., Oba, K., & Naito, K. (2003) · Clinical Genetics · doi:10.1034/j.1399-0004.2003.00035.x · Cited by 24
Molecular Markers for Early Detection of Renal Carcinoma
Skates, S. J., & Iliopoulos, O. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-050010 · Cited by 24
Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations
Stoyanova, R. S., Clapper, M. L., Bellacosa, A., Henske, E. P., Testa, J. R., Ross, E. A., Yeung, A. T., Nicolas, É., Tsichlis, N., Li, Y.-S., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.12.1459 · Cited by 24
Self-citation
Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation
Decker, H.-J. H., Neuhaus, C., Jauch, A. S., Speicher, M. R., Ried, T., Bujard, M., Brauch, H. B., Störkel, S., Stöckle, M., Seliger, B., et al. (1996) · Human Genetics · doi:10.1007/bf02346188 · Cited by 24
Self-citation
The DIRC1 gene at chromosome 2q33 spans a familial RCC-associated t(2;3)(q33;q21) chromosome translocation
Druck, T., Podolski, J., Byrski, T., Wyrwicz, L. S., Zajączek, S., Kata, G., Borówka, A., Lubiński, J., & Huebner, K. (2001) · Journal of Human Genetics · doi:10.1007/s100380170025 · Cited by 24
Binding of elongin A or a von Hippel–Lindau peptide stabilizes the structure of yeast elongin C
Botuyan, M. V., Koth, C. M., Mer, G., Chakrabartty, A., Conaway, J. W., Conaway, R. C., Edwards, A. M., Arrowsmith, C. H., & Chazin, W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9033 · Cited by 24
Interplay between dietary inducers of GST and theGSTM-1 genotype in colon cancer
Slattery, M. L., Kampman, E., Samowitz, W. S., Caan, B. J., & Potter, J. D. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000901)87:5 · Cited by 2
Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin
Schmit, K., Chen, J., Ayama-Canden, S., Fransolet, M., Finet, L., Demazy, C., D'Hondt, L. A., Graux, C., & Michiels, C. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2088-x · Cited by 23
The von Hippel–Lindau tumour suppressor gene: uncovering the expression of the pVHL172 isoform
Chesnel, F., Hascoët, P., Gagné, J., Couturier, A., Jouan, F., Poirier, G. G., Goff‐Gaillard, C. L., Vigneau, C. M., Danger, Y., Vérité, F., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.189 · Cited by 23
Oligoarray comparative genomic hybridization of renal cell tumors that developed in patients with acquired cystic renal disease
Kuntz, E., Yusenko, M. V., Nagy, A., & Kovács, G. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.09.022 · Cited by 23
Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study
Mai, K. T., Faraji, H., Desantis, D. J., Robertson, S. J., Belanger, E. C., & Levac, J. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0871-2 · Cited by 23
La génétique des paragangliomes et des phéochromocytomes
Favier, J., & Gimenez‐Roqueplo, A. (2012) · médecine/sciences · doi:10.1051/medsci/2012286016 · Cited by 23
Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma
Cros, J. F., Sbidian, É., Posseme, K., Letierce, A., Guettier, C., Benoît, G., & Ferlicot, S. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1973-2 · Cited by 23
Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma
Gao, X. Y., & McDermott, D. F. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000323 · Cited by 23
Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation
Gomy, I., de Molfetta, G. A., Barreto, E. A., Ferreira, C. A., Zanette, D. L., da Rocha, J. C. C., & Silva, W. A. (2010) · Familial Cancer · doi:10.1007/s10689-010-9357-2 · Cited by 23
Genetic progression of renal cell carcinoma
Moch, H., & Mihatsch, M. J. (2002) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-002-0685-y · Cited by 23
Molecular genetics of human renal cell tumours
Kovács, G. (1996) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/11.supp6.62 · Cited by 23
Candidate Tumor Suppressor and pVHL Partner Jade-1 Binds and Inhibits AKT in Renal Cell Carcinoma
Zeng, L., Bai, M., Mittal, A. K., El-Jouni, W., Zhou, J., Cohen, D., Zhou, M. I., & Cohen, H. T. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4707 · Cited by 23
Overexpression of anion exchanger 2 in human hepatocellular carcinoma.
Wu, T.-T., Hsieh, Y., Wu, C., Tsai, J.-H., Hsieh, Y., Huang, C., & Liu, J. Y. (2006) · PubMed · Cited by 23
A tumor‐specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas
Ogura, M., Shibata, T., Yi, J., Liu, J., Qu, R., Harada, H., & Hiraoka, M. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00044.x · Cited by 24
Patterns of aneuploidy in stage IV clear cell renal cell carcinoma revealed by comparative genomic hybridization and spectral karyotyping
Pavlovich, C. P., Padilla‐Nash, H. M., Wangsa, D., Nickerson, M. L., Matrosova, V. Y., Linehan, W. M., Ried, T., & Phillips, J. L. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10209 · Cited by 23
Self-citation
Germline and Somatic Mutations in von Hippel-Lindau Disease Gene and Its Significance in the Development of Kidney Cancer
Shuin, T., Kondo, K., Ashida, S., Okuda, H., Yoshida, M., Kanno, H., & Yao, M. (1999) · KARGER eBooks · doi:10.1159/000059976 · Cited by 23
Cytogenetic characterization of a familial papillary renal cell carcinoma
Bernués, M., Casadevall, C., Miró, R., Caballín, M. R., Villavicencio, H., SALVADOR-BAYARRI, J., Zamarrón, A., & Egozcue, J. (1995) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(95)00044-5 · Cited by 23
Molecular genetic analysis of the von Hippel-Lindau disease (VHl) tumour suppressor gene in gonadal tumours
Foster, K., Osborne, R. J., Huddart, R. A., Affara, N. A., Ferguson-Smith, M. A., & Maher, E. R. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00437-8 · Cited by 23
Mutations inras oncogenes: Rare events in ultraviolet B radiation-induced mouse skin tumorigenesis
Khan, S. G., Mohan, R. R., Katiyar, S. K., Wood, G. S., Bickers, D. R., Mukhtar, H., & Agarwal, R. (1996) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199602)15:2 · Cited by 14
Stem Cells, Biomarkers and Genetic Profiling: Approaching Future Challenges in Urology
Mancini, M., Zazzara, M., & Zattoni, F. (2016) · Urologia Journal · doi:10.5301/uro.5000165 · Cited by 22
Etiologic heterogeneity of clear‐cell and papillary renal cell carcinoma in the Netherlands Cohort Study
van de Pol, J. A. A., George, L., van den Brandt, P. A., Baldewijns, M. M. L. L., & Schouten, L. J. (2020) · International Journal of Cancer · doi:10.1002/ijc.33193 · Cited by 22
VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.
Minardi, D., Lucarini, G., Santoni, M., Roberta Mazzucchelli, A., Burattini, L., Pistelli, M., Bianconi, M., Primio, R. D., Scartozzi, M., Montironi, R., et al. (2013) · PubMed · Cited by 22
Anti-angiogenesis approach to genitourinary cancer treatment
Aragon‐Ching, J. B., & Dahut, W. L. (2009) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2009.05.002 · Cited by 22
Chemokines as therapeutic targets in renal cell carcinoma
Reckamp, K. L., Strieter, R. M., & Figlin, R. A. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.6.887 · Cited by 22
Review: Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions
Heng, D. Y. C., Kollmannsberger, C., & Chi, K. N. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009352498 · Cited by 22
[Hypoxia in cancer malignity. Review].
Arvelo, F. A., & Cotte, C. (2009) · PubMed · Cited by 22

Authors: Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D. R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, H., Pomer, S., Brooks, J. D., Isaacs, W. B., Lerman, M. I., Zbar, B., & Linehan, W. M.
Affiliations: National Cancer Institute (US)
Frederick National Laboratory for Cancer Research (US)
National Institutes of Health (US)
Cornell University (US)
University of Michigan (US)
Technical University of Munich (DE)
Heidelberg University (DE)
Johns Hopkins University (US)
ORCID: Gnarra, J.R.
Schmidt, L.
Wei, M.H.
Lubensky, I.
Bander, N.H.
Brauch, H.
Brooks, J.D.
Isaacs, W.B.
Lerman, M.I.
Linehan, W.M.
Venue: Nature Genetics
Publisher: Springer Science and Business Media LLC
Published: 1994-05
Volume: 7
Issue: 1
Pages: 85-90
ISSN: 1061-4036 (ISSN-L)
1546-1718
DOI: 10.1038/ng0594-85
OpenAlex: W2010160635
Cited by: 1,730
References: 29
Citations by year: 2026: 17 · 2025: 25 · 2024: 30 · 2023: 38 · 2022: 38 · 2021: 45 · 2020: 56 · 2019: 47 · 2018: 45 · 2017: 42 · 2016: 57 · 2015: 35 · 2014: 70 · 2013: 66 · 2012: 62
FWCI: 61.77
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Genetics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Health Sciences › Medicine › Oncology › Ear and Head Tumors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords: VHL gene, von Hippel-Lindau disease, renal carcinoma, clear cell renal cell carcinoma, loss of heterozygosity
MeSH terms: Base Sequence, Carcinoma, DNA Mutational Analysis, DNA, Neoplasm, von Hippel-Lindau Disease, Humans, Kidney Neoplasms, Molecular Sequence Data, Mutation, Organ Specificity, Polymorphism, Restriction Fragment Length, Genes, Tumor Suppressor, Neoplasms, Second Primary, Sequence Deletion, Adenocarcinoma, Clear Cell

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutations of the VHL tumour suppressor gene in renal carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks